According to filings with the U.S. Securities and Exchange Commission, ChromaCode is raising up to $4,999,997.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About ChromaCode
ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[x], Luminex, and Caltech. We leverage patented mathematical methods and algorithmic enhancements to enrich signal processing from the most popular life science instrumentation. We are using this to extract new information on biochemistry reactions and substantially increase the performance capabilities of todays gold-standard biochemical assays at a very low cost.

To learn more about ChromaCode, visit http://chromacode.com/
ChromaCode Linkedin Page: https://www.linkedin.com/company/chromacode-inc./

Contact:
Paul Flook, Chief Executive Officer
442-244-4370
https://www.linkedin.com/in/paulflook/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.